High-throughput screen of natural product libraries for Hsp90 inhibitors

Biology

Volumn 3, Issue 1, 2014, Pages 101-138

  Davenport, Jason ^a   Balch, Maurie ^a   Galam, Lakshmi ^a,c   Girgis, Antwan ^b   Hall, Jessica ^b   Blagg, Brian S J ^b   Matts, Robert L ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

High throughput screen; Hsp90; Hsp90 inhibitors; Natural products libraries

Indexed keywords

EID: 84901312344     PISSN: None     EISSN: 20797737     Source Type: Journal    
DOI: 10.3390/biology3010101     Document Type: Article

References (200)

1. Whitesell, L.; Mimnaugh, E.G.; de Costa, B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein hsp90-pp60v-Src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8328.
2. Grenert, J.P.; Sullivan, W.P.; Fadden, P.; Haystead, T.A.; Clark, J.; Mimnaugh, E.; Krutzsch, H.; Ochel, H.J.; Schulte, T.W.; Sausville, E.; et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. 1997, 272, 23843-23850.
3. Sharma, S.V.; Agatsuma, T.; Nakano, H. Targeting of the protein chaperone, Hsp90, by the transformation suppressing agent, radicicol. Oncogene 1998, 16, 2639-2645.
4. Schulte, T.W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L.M. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998, 3, 100-108.
5. Roe, S.M.; Prodromou, C.; O'Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42, 260-266.
6. Theodoraki, M.A.; Caplan, A.J. Quality control and fate determination of Hsp90 client proteins. Biochim. Biophys. Acta 2012, 1823, 683-688.
7. Richter, K.; Buchner, J. Hsp90: Chaperoning signal transduction. J. Cell. Physiol. 2001, 188, 281-290.
8. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
9. Bishop, S.C.; Burlison, J.A.; Blagg, B.S. Hsp90: A novel target for the disruption of multiple signaling cascades. Curr. Cancer Drug Targets 2007, 7, 369-388.
10. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 2012, 18, 64-76.
11. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M.F.; Fritz, L.C.; Burrows, F.J. A high-affinity conformation of hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
12. Whitesell, L.; Shifrin, S.D.; Schwab, G.; Neckers, L.M. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to Src kinase inhibition. Cancer Res. 1992, 52, 1721-1728.
13. Calcul, L.; Zhang, B.; Jinwal, U.K.; Dickey, C.A.; Baker, B.J. Natural products as a rich source of tau-targeting drugs for Alzheimer's disease. Future Med. Chem. 2012, 4, 1751-1761.
14. Waza, M.; Adachi, H.; Katsuno, M.; Minamiyama, M.; Tanaka, F.; Doyu, M.; Sobue, G. Modulation of Hsp90 function in neurodegenerative disorders: A molecular-targeted therapy against disease-causing protein. J. Mol. Med. 2006, 84, 635-646.
15. Ansar, S.; Burlison, J.A.; Hadden, M.K.; Yu, X.M.; Desino, K.E.; Bean, J.; Neckers, L.; Audus, K.L.; Michaelis, M.L.; Blagg, B.S. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg. Med. Chem. Lett. 2007, 17, 1984-1990.
16. Chen, G.; Cao, P.; Goeddel, D.V. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol. Cell 2002, 9, 401-410.
17. Salminen, A.; Paimela, T.; Suuronen, T.; Kaarniranta, K. Innate immunity meets with cellular stress at the IKK complex: Regulation of the IKK complex by Hsp70 and Hsp90. Immunol. Lett. 2008, 117, 9-15.
18. Garcia-Cardena, G.; Fan, R.; Shah, V.; Sorrentino, R.; Cirino, G.; Papapetropoulos, A.; Sessa, W.C. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998, 392, 821-824.
19. Chatterjee, A.; Black, S.M.; Catravas, J.D. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul. Pharmacol. 2008, 49, 134-140.
20. Miyata, Y.; Nakamoto, H.; Neckers, L. The therapeutic target Hsp90 and cancer hallmarks. Curr. Pharm. Des. 2013, 19, 347-365.
21. Hong, D.S.; Banerji, U.; Tavana, B.; George, G.C.; Aaron, J.; Kurzrock, R. Targeting the molecular chaperone heat shock protein 90 (Hsp90): Lessons learned and future directions. Cancer Treat. Rev. 2013, 39, 375-387.
22. Geller, R.; Taguwa, S.; Frydman, J. Broad action of Hsp90 as a host chaperone required for viral replication. Biochim. Biophys. Acta 2012, 1823, 698-706.
23. Wirk, B., Heat shock protein inhibitors for the treatment of fungal infections. Recent Pat. Antiinfect. Drug Discov. 2011, 6, 38-44.
24. Shonhai, A.; Maier, A.G.; Przyborski, J.M.; Blatch, G.L. Intracellular protozoan parasites of humans: The role of molecular chaperones in development and pathogenesis. Protein Pept. Lett. 2011, 18, 143-157.
25. Shonhai, A. Plasmodial heat shock proteins: Targets for chemotherapy. FEMS Immunol. Med. Microbiol. 2010, 58, 61-74.
26. Matts, R.; Manjarrez, J.R. Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action. Curr. Top. Med. Chem. 2009, 9, 1462-1478.
27. Thulasiraman, V.; Matts, R.L. Luciferase renaturation assays of chaperones and chaperone antagonists. In Methods in Molecular biology: Bioluminescent Protocols; LaRossa, R., Ed.; Humana Press, Inc.: Totowa, NJ, USA, 1997; Chapter 11.
28. Thulasiraman, V.; Matts, R.L. Effect of geldanamycin on the kinetics of chaperone-mediated renaturation of firefly luciferase in rabbit reticulocyte lysate. Biochemistry 1996, 35, 13443-13450.
29. Galam, L.; Hadden, M.K.; Ma, Z.; Ye, Q.Z.; Yun, B.G.; Blagg, B.S.; Matts, R.L. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorg. Med. Chem. 2007, 15, 1939-1946.
30. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311-335.
31. Cragg, G.M.; Grothaus, P.G.; Newman, D.J. Impact of natural products on developing new anti-cancer agents. Chem. Rev. 2009, 109, 3012-3043.
32. Huber, P.J. Robust Statistics; Wiley: New York, NY, USA, 1981; p 308.
33. Davenport, J.; Manjarrez, J.R.; Peterson, L.; Krumm, B.; Blagg, B.S.; Matts, R.L. Gambogic acid, a natural product inhibitor of Hsp90. J. Nat. Prod. 2011, 74, 1085-1092.
34. Schumacher, R.J.; Hurst, R.; Sullivan, W.P.; McMahon, N.J.; Toft, D.O.; Matts, R.L. ATP-dependent chaperoning activity of reticulocyte lysate. J. Biol. Chem. 1994, 269, 9493-9499.
35. Koga, F.; Kihara, K.; Neckers, L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res. 2009, 29, 797-807.
36. Burch, A.D.; Weller, S.K. Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone Hsp90 for proper localization to the nucleus. J. Virol. 2005, 79, 10740-10749.
37. Kampmueller, K.M.; Miller, D.J. The cellular chaperone heat shock protein 90 facilitates flock house virus rna replication in drosophila cells. J. Virol. 2005, 79, 6827-6837.
38. Bruns, A.F.; Yuldasheva, N.; Latham, A.M.; Bao, L.; Pellet-Many, C.; Frankel, P.; Stephen, S.L.; Howell, G.J.; Wheatcroft, S.B.; Kearney, M.T.; et al. A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair. PLoS One 2012, 7, e48539.
39. Staufer, K.; Stoeltzing, O. Implication of heat shock protein 90 (Hsp90) in tumor angiogenesis: A molecular target for anti-angiogenic therapy? Curr. Cancer Drug Targets 2010, 10, 890-897.
40. Ghantous, A.; Gali-Muhtasib, H.; Vuorela, H.; Saliba, N.A.; Darwiche, N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov. Today 2010, 15, 668-678.
41. Geetha, B.S.; Nair, M.S.; Latha, P.G.; Remani, P. Sesquiterpene lactones isolated from Elephantopus scaber l. Inhibits human lymphocyte proliferation and the growth of tumour cell lines and induces apoptosis in vitro. J. Biomed. Biotechnol. 2012, 2012, 721285.
42. Duraipandiyan, V.; Al-Harbi, N.A.; Ignacimuthu, S.; Muthukumar, C. Antimicrobial activity of sesquiterpene lactones isolated from traditional medicinal plant, Costus speciosus (koen ex. Retz.) sm. BMC Complement. Altern. Med. 2012, 12, 13.
43. Kim, Y.H.; Choo, S.J.; Ryoo, I.J.; Ahn, J.S.; Yoo, I.D. Eudesmanolides from Taraxacum mongolicum and their inhibitory effects on the production of nitric oxide. Arch. Pharm. Res. 2011, 34, 37-41.
44. Yamashita, Y.; Ikeda, T.; Matsuda, M.; Maji, D.; Hoshino, T.; Mizushima, T. Purification and characterization of Hsp-inducers from Eupatorium lindleyanum. Biochem. Pharmacol. 2012, 83, 909-922.
45. Kwok, B.H.; Koh, B.; Ndubuisi, M.I.; Elofsson, M.; Crews, C.M. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkappaB kinase. Chem. Biol. 2001, 8, 759-766.
46. Carlisi, D.; D'Anneo, A.; Angileri, L.; Lauricella, M.; Emanuele, S.; Santulli, A.; Vento, R.; Tesoriere, G. Parthenolide sensitizes hepatocellular carcinoma cells to TRIAL by inducing the expression of death receptors through inhibition of STAT3 activation. J. Cell. Physiol. 2011, 226, 1632-1641.
47. Hoffmann, R.; von Schwarzenberg, K.; Lopez-Anton, N.; Rudy, A.; Wanner, G.; Dirsch, V.M.; Vollmar, A.M. Helenalin bypasses Bcl-2-mediated cell death resistance by inhibiting NF-kappaB and promoting reactive oxygen species generation. Biochem. Pharmacol. 2011, 82, 453-463.
48. Berges, C.; Fuchs, D.; Opelz, G.; Daniel, V.; Naujokat, C. Helenalin suppresses essential immune functions of activated CD4+ T cells by multiple mechanisms. Mol. Immunol. 2009, 46, 2892-2901.
49. Huang, P.R.; Yeh, Y.M.; Wang, T.C. Potent inhibition of human telomerase by helenalin. Cancer Lett. 2005, 227, 169-174.
50. Li, J.; Du, L.; Kelly, M.; Zhou, Y.D.; Nagle, D.G. Structures and potential antitumor activity of sesterterpenes from the marine sponge Hyrtios communis. J. Nat. Prod. 2013, 76, 1492-1497.
51. Xie, Y.; Liu, L.; Huang, X.; Guo, Y.; Lou, L. Scalaradial inhibition of epidermal growth factor receptor-mediated Akt phosphorylation is independent of secretory phospholipase A2. J. Pharmacol. Exp. Ther. 2005, 314, 1210-1217.
52. Liu, H.; Edrada-Ebel, R.; Ebel, R.; Wang, Y.; Schulz, B.; Draeger, S.; Muller, W.E.; Wray, V.; Lin, W.; Proksch, P. Drimane sesquiterpenoids from the fungus Aspergillus ustus isolated from the marine sponge Suberites domuncula. J. Nat. Prod. 2009, 72, 1585-1588.
53. Kaur, K.; Jain, M.; Kaur, T.; Jain, R. Antimalarials from nature. Bioorg. Med. Chem. 2009, 17, 3229-3256.
54. Pettit, G.R.; Cragg, G.M. Antineoplastic agents. 32. The pseudoguaianolide helenalin. Experientia 1973, 29, 781.
55. Lim, C.B.; Fu, P.Y.; Ky, N.; Zhu, H.S.; Feng, X.; Li, J.; Srinivasan, K.G.; Hamza, M.S.; Zhao, Y. NF-kappaB p65 repression by the sesquiterpene lactone, helenalin, contributes to the induction of autophagy cell death. BMC Complement. Altern. Med. 2012, 12, 93.
56. Halder, B.; Das Gupta, S.; Gomes, A. Black tea polyphenols induce human leukemic cell cycle arrest by inhibiting Akt signaling: Possible involvement of hsp90, Wnt/beta-catenin signaling and FOXO1. FEBS J. 2012, 279, 2876-2891.
57. Miyamoto, K.; Nomura, M.; Murayama, T.; Furukawa, T.; Hatano, T.; Yoshida, T.; Koshiura, R.; Okuda, T. Antitumor activities of ellagitannins against sarcoma-180 in mice. Biol. Pharm. Bull. 1993, 16, 379-387.
58. Nakashima, H.; Murakami, T.; Yamamoto, N.; Sakagami, H.; Tanuma, S.; Hatano, T.; Yoshida, T.; Okuda, T. Inhibition of human immunodeficiency viral replication by tannins and related compounds. Antiviral Res. 1992, 18, 91-103.
59. Zu, M.; Yang, F.; Zhou, W.; Liu, A.; Du, G.; Zheng, L. In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives. Antiviral Res. 2012, 94, 217-224.
60. Kim, S.; Joo, Y.E. Theaflavin inhibits LPS-induced IL-6, MCP-1, and ICAM-1 expression in bone marrow-derived macrophages through the blockade of NF-kappaB and MAPK signaling pathways. Chonnam. Med. J. 2011, 47, 104-110.
61. Wang, X.; Howell, C.P.; Chen, F.; Yin, J.; Jiang, Y. Gossypol-A polyphenolic compound from cotton plant. Adv. Food Nutr. Res. 2009, 58, 215-263.
62. Krenn, L.; Presser, A.; Pradhan, R.; Bahr, B.; Paper, D.H.; Mayer, K.K.; Kopp, B. Sulfemodin 8-O-beta-D-glucoside, a new sulfated anthraquinone glycoside, and antioxidant phenolic compounds from Rheum emodi. J. Nat. Prod. 2003, 66, 1107-1109.
63. Kageura, T.; Matsuda, H.; Morikawa, T.; Toguchida, I.; Harima, S.; Oda, M.; Yoshikawa, M. Inhibitors from rhubarb on lipopolysaccharide-induced nitric oxide production in macrophages: Structural requirements of stilbenes for the activity. Bioorg. Med. Chem. 2001, 9, 1887-1893.
64. Tereschuk, M.L.; Riera, M.V.; Castro, G.R.; Abdala, L.R. Antimicrobial activity of flavonoids from leaves of Tagetes minuta. J. Ethnopharmacol. 1997, 56, 227-232.
65. Ikigai, H.; Nakae, T.; Hara, Y.; Shimamura, T. Bactericidal catechins damage the lipid bilayer. Biochim. Biophys. Acta 1993, 1147, 132-136.
66. Yin, Z.; Henry, E.C.; Gasiewicz, T.A. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 2009, 48, 336-345.
67. Sanchez, I.; Gomez-Garibay, F.; Taboada, J.; Ruiz, B.H. Antiviral effect of flavonoids on the dengue virus. Phytother. Res. 2000, 14, 89-92.
68. Kole, L.; Giri, B.; Manna, S.K.; Pal, B.; Ghosh, S. Biochanin-A, an isoflavon, showed anti-proliferative and anti-inflammatory activities through the inhibition of iNOS expression, p38-MAPK and ATF-2 phosphorylation and blocking NFkappaB nuclear translocation. Eur. J. Pharmacol. 2011, 653, 8-15.
69. Choi, A.Y.; Choi, J.H.; Yoon, H.; Hwang, K.Y.; Noh, M.H.; Choe, W.; Yoon, K.S.; Ha, J.; Yeo, E.J.; Kang, I. Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in neuro-2A mouse neuroblastoma cells. Eur. J. Pharmacol. 2011, 668, 115-126.
70. Xagorari, A.; Papapetropoulos, A.; Mauromatis, A.; Economou, M.; Fotsis, T.; Roussos, C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J. Pharmacol. Exp. Ther. 2001, 296, 181-187.
71. Lee, E.J.; Oh, S.Y.; Sung, M.K. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem. Toxicol. 2012, 50, 4136-4143.
72. Fu, J.; Chen, D.; Zhao, B.; Zhao, Z.; Zhou, J.; Xu, Y.; Xin, Y.; Liu, C.; Luo, L.; Yin, Z. Luteolin induces carcinoma cell apoptosis through binding Hsp90 to suppress constitutive activation of STAT3. PLoS One 2012, 7, e49194.
73. Watanapokasin, R.; Jarinthanan, F.; Nakamura, Y.; Sawasjirakij, N.; Jaratrungtawee, A.; Suksamrarn, S. Effects of alpha-mangostin on apoptosis induction of human colon cancer. World J. Gastroenterol. 2011, 17, 2086-2095.
74. Johnson, J.J.; Petiwala, S.M.; Syed, D.N.; Rasmussen, J.T.; Adhami, V.M.; Siddiqui, I.A.; Kohl, A.M.; Mukhtar, H. Alpha-mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth. Carcinogenesis 2012, 33, 413-419.
75. Akao, Y.; Nakagawa, Y.; Iinuma, M.; Nozawa, Y. Anti-cancer effects of xanthones from pericarps of mangosteen. Int. J. Mol. Sci. 2008, 9, 355-370.
76. Zhang, T.; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C.G.; Sun, D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 2008, 7, 162-170.
77. Hadden, M.K.; Galam, L.; Gestwicki, J.E.; Matts, R.L.; Blagg, B.S. Derrubone, an inhibitor of the Hsp90 protein folding machinery. J. Nat. Prod. 2007, 70, 2014-2018.
78. Cushnie, T.P.; Lamb, A.J. Antimicrobial activity of flavonoids. Int. J. Antimicrob. Agents 2005, 26, 343-356.
79. Liu, L.Z.; Fang, J.; Zhou, Q.; Hu, X.; Shi, X.; Jiang, B.H. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: Implication of chemoprevention of lung cancer. Mol. Pharmacol. 2005, 68, 635-643.
80. Fang, J.; Zhou, Q.; Liu, L.Z.; Xia, C.; Hu, X.; Shi, X.; Jiang, B.H. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 2007, 28, 858-864.
81. Opletalova, V.; Sedivy, D. [Chalcones and their heterocyclic analogs as potential antifungal chemotherapeutic agents]. Ceska. Slov. Farm. 1999, 48, 252-255.
82. Herencia, F.; Ferrandiz, M.L.; Ubeda, A.; Guillen, I.; Dominguez, J.N.; Charris, J.E.; Lobo, G.M.; Alcaraz, M.J. Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 in mouse peritoneal macrophages. FEBS Lett. 1999, 453, 129-134.
83. Makita, H.; Tanaka, T.; Fujitsuka, H.; Tatematsu, N.; Satoh, K.; Hara, A.; Mori, H. Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin. Cancer Res. 1996, 56, 4904-4909.
84. Casano, G.; Dumetre, A.; Pannecouque, C.; Hutter, S.; Azas, N.; Robin, M. Anti-HIV and antiplasmodial activity of original flavonoid derivatives. Bioorg. Med. Chem. 2010, 18, 6012-6023.
85. Yadav, V.R.; Prasad, S.; Sung, B.; Aggarwal, B.B. The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int. Immunopharmacol. 2011, 11, 295-309.
86. Salminen, A.; Lehtonen, M.; Paimela, T.; Kaarniranta, K. Celastrol: Molecular targets of thunder god vine. Biochem. Biophys. Res. Commun. 2010, 394, 439-442.
87. Patwardhan, C.A.; Fauq, A.; Peterson, L.B.; Miller, C.; Blagg, B.S.; Chadli, A. Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. J. Biol. Chem. 2013, 288, 7313-7325.
88. Brandt, G.E.; Schmidt, M.D.; Prisinzano, T.E.; Blagg, B.S. Gedunin, a novel hsp90 inhibitor: Semisynthesis of derivatives and preliminary structure-activity relationships. J. Med. Chem. 2008, 51, 6495-6502.
89. Kim, M.S.; Kwon, J.Y.; Kang, N.J.; Lee, K.W.; Lee, H.J. Phloretin induces apoptosis in H-Ras MCF10A human breast tumor cells through the activation of p53 via Jnk and p38 mitogen-activated protein kinase signaling. Ann. N. Y. Acad. Sci. 2009, 1171, 479-483.
90. Esatbeyoglu, T.; Huebbe, P.; Ernst, I.M.; Chin, D.; Wagner, A.E.; Rimbach, G. Curcumin-From molecule to biological function. Angew. Chem. Int. Ed. Engl. 2012, 51, 5308-5332.
91. Giommarelli, C.; Zuco, V.; Favini, E.; Pisano, C.; Dal Piaz, F.; de Tommasi, N.; Zunino, F. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell. Mol. Life Sci. 2010, 67, 995-1004.
92. Han, A.R.; Kang, Y.J.; Windono, T.; Lee, S.K.; Seo, E.K. Prenylated flavonoids from the heartwood of Artocarpus communis with inhibitory activity on lipopolysaccharide-induced nitric oxide production. J. Nat. Prod. 2006, 69, 719-721.
93. Gafner, S.; Wolfender, J.L.; Mavi, S.; Hostettmann, K. Antifungal and antibacterial chalcones from Myrica serrata. Planta Med. 1996, 62, 67-69.
94. Belofsky, G.; Percivill, D.; Lewis, K.; Tegos, G.P.; Ekart, J. Phenolic metabolites of Dalea versicolor that enhance antibiotic activity against model pathogenic bacteria. J. Nat. Prod. 2004, 67, 481-484.
95. Ko, H.; Kim, Y.J.; Amor, E.C.; Lee, J.W.; Kim, H.C.; Kim, H.J.; Yang, H.O. Induction of autophagy by dimethyl cardamonin is associated with proliferative arrest in human colorectal carcinoma HCT116 and LOVO cells. J. Cell. Biochem. 2011, 112, 2471-2479.
96. Kim, Y.J.; Ko, H.; Park, J.S.; Han, I.H.; Amor, E.C.; Lee, J.W.; Yang, H.O. Dimethyl cardamonin inhibits lipopolysaccharide-induced inflammatory factors through blocking NF-kappaB p65 activation. Int. Immunopharmacol. 2010, 10, 1127-1134.
97. Ye, C.L.; Qian, F.; Wei, D.Z.; Lu, Y.H.; Liu, J.W. Induction of apoptosis in K562 human leukemia cells by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone. Leuk. Res. 2005, 29, 887-892.
98. Ye, C.L.; Liu, J.W.; Wei, D.Z.; Lu, Y.H.; Qian, F. In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model. Cancer Chemother. Pharmacol. 2005, 56, 70-74.
99. Friedlander, T.W.; Weinberg, V.K.; Huang, Y.; Mi, J.T.; Formaker, C.G.; Small, E.J.; Harzstark, A.L.; Lin, A.M.; Fong, L.; Ryan, C.J. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol. Rep. 2012, 27, 3-9.
100. Zhang, Y.; Xu, S.; Lin, J.; Yao, G.; Han, Z.; Liang, B.; Zou, Z.; Chen, Z.; Song, Q.; Dai, Y.; et al. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo. Breast Cancer Res. Treat. 2012, 136, 379-388.
101. Maioli, E.; Torricelli, C.; Valacchi, G. Rottlerin and cancer: Novel evidence and mechanisms. Sci. World J. 2012, 2012, 350826.
102. Torricelli, C.; Salvadori, S.; Valacchi, G.; Soucek, K.; Slabakova, E.; Muscettola, M.; Volpi, N.; Maioli, E. Alternative pathways of cancer cell death by rottlerin: Apoptosis versus autophagy. Evid. Based Complement. Alternat. Med. 2012, 2012, 980658.
103. Singh, B.N.; Kumar, D.; Shankar, S.; Srivastava, R.K. Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells. Biochem. Pharmacol. 2012, 84, 1154-1163.
104. Maioli, E.; Torricelli, C.; Valacchi, G. Rottlerin and curcumin: A comparative analysis. Ann. N. Y. Acad. Sci. 2012, 1259, 65-76.
105. Lee, S.E.; Kim, M.R.; Kim, J.H.; Takeoka, G.R.; Kim, T.W.; Park, B.S. Antimalarial activity of anthothecol derived from Khaya anthotheca (meliaceae). Phytomedicine 2008, 15, 533-535.
106. Souto, A.L.; Tavares, J.F.; da Silva, M.S.; Diniz Mde, F.; de Athayde-Filho, P.F.; Barbosa Filho, J.M. Anti-inflammatory activity of alkaloids: An update from 2000 to 2010. Molecules 2011, 16, 8515-8534.
107. Cortijo, J.; Villagrasa, V.; Pons, R.; Berto, L.; Marti-Cabrera, M.; Martinez-Losa, M.; Domenech, T.; Beleta, J.; Morcillo, E.J. Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes. Br. J. Pharmacol. 1999, 127, 1641-1651.
108. Lamchouri, F.; Zemzami, M.; Jossang, A.; Abdellatif, A.; Israili, Z.H.; Lyoussi, B. Cytotoxicity of alkaloids isolated from Peganum harmala seeds. Pak. J. Pharm. Sci. 2013, 26, 699-706.
109. Ignacimuthu, S.; Shanmugam, N. Antimycobacterial activity of two natural alkaloids, vasicine acetate and 2-acetyl benzylamine, isolated from indian shrub Adhatoda vasica ness. Leaves. J. Biosci. 2010, 35, 565-570.
110. Misra, P.; Khaliq, T.; Dixit, A.; SenGupta, S.; Samant, M.; Kumari, S.; Kumar, A.; Kushawaha, P.K.; Majumder, H.K.; Saxena, A.K.; et al. Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: An approach for rational drug design. J. Antimicrob. Chemother. 2008, 62, 998-1002.
111. Khaliq, T.; Misra, P.; Gupta, S.; Reddy, K.P.; Kant, R.; Maulik, P.R.; Dube, A.; Narender, T. Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg. Med. Chem. Lett. 2009, 19, 2585-2586.
112. Trebec-Reynolds, D.P.; Voronov, I.; Heersche, J.N.; Manolson, M.F. VEGF-A expression in osteoclasts is regulated by NF-kappaB induction of HIF-1alpha. J. Cell. Biochem. 2010, 110, 343-351.
113. Rightsel, W.A.; Schneider, H.G.; Sloan, B.J.; Graf, P.R.; Miller, F.A.; Bartz, O.R.; Ehrlich, J.; Dixon, G.J. Antiviral activity of gliotoxin and gliotoxin acetate. Nature 1964, 204, 1333-1334.
114. Frenzel, A.; Zirath, H.; Vita, M.; Albihn, A.; Henriksson, M.A. Identification of cytotoxic drugs that selectively target tumor cells with Myc overexpression. PLoS One 2011, 6, e27988.
115. Genne, P.; Duchamp, O.; Solary, E.; Magnette, J.; Belon, J.P.; Chauffert, B. Cinchonine per os: Efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anticancer Drug Des. 1995, 10, 103-118.
116. Furstner, A. Chemistry and biology of roseophilin and the prodigiosin alkaloids: A survey of the last 2500 years. Angew. Chem. Int. Ed. Engl. 2003, 42, 3582-3603.
117. Liu, R.; Cui, C.B.; Duan, L.; Gu, Q.Q.; Zhu, W.M. Potent in vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a sponge-derived Actinomycete saccharopolyspora sp. Nov. Arch. Pharm. Res. 2005, 28, 1341-1344.
118. Warnick-Pickle, D.J.; Byrne, K.M.; Pandey, R.C.; White, R.J. Fredericamycin a, a new antitumor antibiotic. II. Biological properties. J. Antibiot. 1981, 34, 1402-1407.
119. Latham, M.D.; King, C.K.; Gorycki, P.; Macdonald, T.L.; Ross, W.E. Inhibition of topoisomerases by fredericamycin A. Cancer Chemother. Pharmacol. 1989, 24, 167-171.
120. Miao, S.; Shi, X.; Zhang, H.; Wang, S.; Sun, J.; Hua, W.; Miao, Q.; Zhao, Y.; Zhang, C. Proliferation-attenuating and apoptosis-inducing effects of tryptanthrin on human chronic myeloid leukemia K562 cell line in vitro. Int. J. Mol. Sci. 2011, 12, 3831-3845.
121. Boustie, J.; Stigliani, J.L.; Montanha, J.; Amoros, M.; Payard, M.; Girre, L. Antipoliovirus structure-activity relationships of some aporphine alkaloids. J. Nat. Prod. 1998, 61, 480-484.
122. Spasova, M.; Philipov, S.; Nikolaeva-Glomb, L.; Galabov, A.S.; Milkova, T. Cinnamoyl-and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. Bioorg. Med. Chem. 2008, 16, 7457-7461.
123. Kondo, Y.; Imai, Y.; Hojo, H.; Endo, T.; Nozoe, S. Suppression of tumor cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine, and apomorphine. J. Pharmacobiodyn. 1990, 13, 426-431.
124. Dong, X.P.; Mondranondra, I.O.; Che, C.T.; Fong, H.S.; Farnsworth, N.R. Kmeriol and other aromatic constituents of Kmeria duperreana. Pharm. Res. 1989, 6, 637-640.
125. Clark, A.M.; Watson, E.S.; Ashfaq, M.K.; Hufford, C.D. In vivo efficacy of antifungal oxoaporphine alkaloids in experimental disseminated candidiasis. Pharm. Res. 1987, 4, 495-498.
126. Hufford, C.D.; Funderburk, M.J.; Morgan, J.M.; Robertson, L.W. Two antimicrobial alkaloids from heartwood of Liriodendron tulipifera l. J. Pharm. Sci. 1975, 64, 789-792.
127. Woo, S.H.; Reynolds, M.C.; Sun, N.J.; Cassady, J.M.; Snapka, R.M. Inhibition of topoisomerase II by liriodenine. Biochem. Pharmacol. 1997, 54, 467-473.
128. Xu, J.Y.; Meng, Q.H.; Chong, Y.; Jiao, Y.; Zhao, L.; Rosen, E.M.; Fan, S. Sanguinarine inhibits growth of human cervical cancer cells through the induction of apoptosis. Oncol. Rep. 2012, 28, 2264-2270.
129. Gupta, S.C.; Kim, J.H.; Prasad, S.; Aggarwal, B.B. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010, 29, 405-434.
130. Yang, X.J.; Miao, F.; Yao, Y.; Cao, F.J.; Yang, R.; Ma, Y.N.; Qin, B.F.; Zhou, L. In vitro antifungal activity of sanguinarine and chelerythrine derivatives against phytopathogenic fungi. Molecules 2012, 17, 13026-13035.
131. Yu, S.M. Thaliporphine selectively inhibits expression of the inducible, but not the constitutive, nitric oxide synthase. Biochem. J. 1994, 303, 289-294.
132. Graziose, R.; Rathinasabapathy, T.; Lategan, C.; Poulev, A.; Smith, P.J.; Grace, M.; Lila, M.A.; Raskin, I. Antiplasmodial activity of aporphine alkaloids and sesquiterpene lactones from Liriodendron tulipifera l. J. Ethnopharmacol. 2011, 133, 26-30.
133. Remichkova, M.; Dimitrova, P.; Philipov, S.; Ivanovska, N. Toll-like receptor-mediated anti-inflammatory action of glaucine and oxoglaucine. Fitoterapia 2009, 80, 411-414.
134. Yang, X.; Yang, B.; Cai, J.; Zhang, C.; Zhang, Q.; Xu, L.; Qin, Q.; Zhu, H.; Ma, J.; Tao, G.; et al. Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1alpha in vitro and in vivo. Cancer Biol. Ther. 2013, 14, 1066-1073.
135. Pierpaoli, E.; Arcamone, A.G.; Buzzetti, F.; Lombardi, P.; Salvatore, C.; Provinciali, M. Antitumor effect of novel berberine derivatives in breast cancer cells. Biofactors 2013, 39, 672-679.
136. Wu, C.M.; Li, T.M.; Tan, T.W.; Fong, Y.C.; Tang, C.H. Berberine reduces the metastasis of chondrosarcoma by modulating the alpha V beta 3 integrin and the PKC delta, c-Src, and AP-1 signaling pathways. Evid. Based Complement. Alternat. Med. 2013, 2013, 423164.
137. Sellers, R.P.; Alexander, L.D.; Johnson, V.A.; Lin, C.C.; Savage, J.; Corral, R.; Moss, J.; Slugocki, T.S.; Singh, E.K.; Davis, M.R.; et al. Design and synthesis of hsp90 inhibitors: Exploring the SAR of sansalvamide A derivatives. Bioorg. Med. Chem. 2010, 18, 6822-6856.
138. Hale, K.J.; Manaviazar, S.; Lazarides, L.; George, J.; Walters, M.A.; Cai, J.; Delisser, V.M.; Bhatia, G.S.; Peak, S.A.; Dalby, S.M.; et al. Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and PRB. Org. Lett. 2009, 11, 737-740.
139. Korting, H.C.; Schollmann, C.; Stauss-Grabo, M.; Schafer-Korting, M. Antimicrobial peptides and skin: A paradigm of translational medicine. Skin Pharmacol. Physiol. 2012, 25, 323-334.
140. Guo, W.; Reigan, P.; Siegel, D.; Zirrolli, J.; Gustafson, D.; Ross, D. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:Quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol. Pharmacol. 2006, 70, 1194-1203.
141. Dikalov, S.; Landmesser, U.; Harrison, D.G. Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling. Implications for studies of Hsp90 and endothelial cell nitric-oxide synthase. J. Biol. Chem. 2002, 277, 25480-25485.
142. Wimalawansa, S.J. Vitamin D in the new millennium. Curr. Osteoporos. Rep. 2012, 10, 4-15.
143. Wigington, D.P.; Strugnell, S.A.; Knutson, J.C. Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells. Anticancer Res. 2005, 25, 1909-1917.
144. Simeone, A.M.; Tari, A.M. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell. Mol. Life Sci. 2004, 61, 1475-1484.
145. Abu, J.; Batuwangala, M.; Herbert, K.; Symonds, P. Retinoic acid and retinoid receptors: Potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol. 2005, 6, 712-720.
146. Barliya, T.; Mandel, M.; Livnat, T.; Weinberger, D.; Lavie, G. Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: A unique cancer therapy. PLoS One 2011, 6, e22849.
147. Sacau, E.P.; Estevez-Braun, A.; Ravelo, A.G.; Ferro, E.A.; Tokuda, H.; Mukainaka, T.; Nishino, H. Inhibitory effects of lapachol derivatives on epstein-barr virus activation. Bioorg. Med. Chem. 2003, 11, 483-488.
148. Park, E.J.; Choi, K.S.; Kwon, T.K. Beta-lapachone-induced reactive oxygen species (ROS) generation mediates autophagic cell death in glioma U87 MG cells. Chem. Biol. Interact. 2011, 189, 37-44.
149. Pardee, A.B.; Li, Y.Z.; Li, C.J. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002, 2, 227-242.
150. Li, C.J.; Zhang, L.J.; Dezube, B.J.; Crumpacker, C.S.; Pardee, A.B. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc. Natl. Acad. Sci. USA 1993, 90, 1839-1842.
151. Guiraud, P.; Steiman, R.; Campos-Takaki, G.M.; Seigle-Murandi, F.; Simeon de Buochberg, M. Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. Planta Med. 1994, 60, 373-374.
152. Duvoix, A.; Delhalle, S.; Blasius, R.; Schnekenburger, M.; Morceau, F.; Fougere, M.; Henry, E.; Galteau, M.M.; Dicato, M.; Diederich, M. Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. Biochem. Pharmacol. 2004, 68, 1101-1111.
153. Cavalcanti, B.C.; Barros, F.W.; Cabral, I.O.; Ferreira, J.R.; Magalhaes, H.I.; Junior, H.V.; da Silva Junior, E.N.; de Abreu, F.C.; Costa, C.O.; Goulart, M.O.; et al. Preclinical genotoxicology of nor-beta-lapachone in human cultured lymphocytes and chinese hamster lung fibroblasts. Chem. Res. Toxicol. 2011, 24, 1560-1574.
154. Boothman, D.A.; Greer, S.; Pardee, A.B. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res. 1987, 47, 5361-5366.
155. Salas, C.O.; Faundez, M.; Morello, A.; Maya, J.D.; Tapia, R.A. Natural and synthetic naphthoquinones active against Trypanosoma cruzi: An initial step towards new drugs for Chagas disease. Curr. Med. Chem. 2011, 18, 144-161.
156. Wilson, J.B.; Johnson, M.A.; Stuckert, A.P.; Trueman, K.L.; May, S.; Bryant, P.E.; Meyn, R.E.; D'Andrea, A.D.; Jones, N.J. The chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange. Carcinogenesis 2001, 22, 1939-1946.
157. Take, Y.; Oogose, K.; Kubo, T.; Inouye, Y.; Nakamura, S.; Kitahara, Y.; Kubo, A. Comparative study on biological activities of heterocyclic quinones and streptonigrin. J. Antibiot. 1987, 40, 679-684.
158. Ross, D.; Beall, H.; Traver, R.D.; Siegel, D.; Phillips, R.M.; Gibson, N.W. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol. Res. 1994, 6, 493-500.
159. Okada, H.; Mukai, H.; Inouye, Y.; Nakamura, S. Biological properties of streptonigrin derivatives. II. Inhibition of reverse transcriptase activity. J. Antibiot. 1986, 39, 306-308.
160. Gu, B.; DeAngelis, L.M. Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs 2005, 16, 167-174.
161. Beall, H.D.; Liu, Y.; Siegel, D.; Bolton, E.M.; Gibson, N.W.; Ross, D. Role of NAD(P)H:Quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem. Pharmacol. 1996, 51, 645-652.
162. Lee, W.Y.; Cheung, C.C.; Liu, K.W.; Fung, K.P.; Wong, J.; Lai, P.B.; Yeung, J.H. Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. J. Nat. Prod. 2010, 73, 854-859.
163. Dat, N.T.; Jin, X.; Lee, J.H.; Lee, D.; Hong, Y.S.; Lee, K.; Kim, Y.H.; Lee, J.J. Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. J. Nat. Prod. 2007, 70, 1093-1097.
164. Suk, F.M.; Jou, W.J.; Lin, R.J.; Lin, S.Y.; Tzeng, F.Y.; Liang, Y.C. 15,16-Dihydrotanshinone I-induced apoptosis in human colorectal cancer cells: Involvement of ATF3. Anticancer Res. 2013, 33, 3225-3231.
165. Padhye, S.; Dandawate, P.; Yusufi, M.; Ahmad, A.; Sarkar, F.H. Perspectives on medicinal properties of plumbagin and its analogs. Med. Res. Rev. 2012, 32, 1131-1138.
166. Lu, J.J.; Bao, J.L.; Wu, G.S.; Xu, W.S.; Huang, M.Q.; Chen, X.P.; Wang, Y.T. Quinones derived from plant secondary metabolites as anti-cancer agents. Anticancer Agents Med. Chem. 2013, 13, 456-463.
167. Grimley, P.M.; Moss, B. Similar effect of rifampin and other rifamycin derivatives on vaccinia virus morphogenesis. J. Virol. 1971, 8, 225-231.
168. Chen, X.; Yang, L.; Oppenheim, J.J.; Howard, M.Z. Cellular pharmacology studies of shikonin derivatives. Phytother. Res. 2002, 16, 199-209.
169. Uehara, Y.; Hori, M.; Takeuchi, T.; Umezawa, H. Screening of agents which convert "transformed morphology" of rous sarcoma virus-infected rat kidney cells to "normal morphology": Identification of an active agent as herbimycin and its inhibition of intracellular Src kinase. Jpn. J. Cancer Res. 1985, 76, 672-675.
170. Sakagami, M.; Morrison, P.; Welch, W.J. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chaperones 1999, 4, 19-28.
171. Omura, S.; Iwai, Y.; Takahashi, Y.; Sadakane, N.; Nakagawa, A.; Oiwa, H.; Hasegawa, Y.; Ikai, T. Herbimycin, a new antibiotic produced by a strain of streptomyces. J. Antibiot. 1979, 32, 255-261.
172. Chiari, E.; de Oliveira, A.B.; Raslan, D.S.; Mesquita, A.A.; Tavares, K.G. Screening in vitro of natural products against blood forms of Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 1991, 85, 372-374.
173. Tan, J.; Chen, B.; He, L.; Tang, Y.; Jiang, Z.; Yin, G.; Wang, J.; Jiang, X. Anacardic acid (6-pentadecylsalicylic acid) induces apoptosis of prostate cancer cells through inhibition of androgen receptor and activation of p53 signaling. Chin. J. Cancer Res. 2012, 24, 275-283.
174. Seong, Y.A.; Shin, P.G.; Yoon, J.S.; Yadunandam, A.K.; Kim, G.D. Induction of the endoplasmic reticulum stress and autophagy in human lung carcinoma A549 cells by anacardic acid. Cell Biochem. Biophys. 2013, doi:10.1007/s12013-013-9717-2.
175. Dixit, D.; Sharma, V.; Ghosh, S.; Koul, N.; Mishra, P.K.; Sen, E. Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic. Biol. Med. 2009, 47, 364-374.
176. Pan, J.; Chen, B.; Su, C.H.; Zhao, R.; Xu, Z.X.; Sun, L.; Lee, M.H.; Yeung, S.C. Autophagy induced by farnesyltransferase inhibitors in cancer cells. Cancer Biol. Ther. 2008, 7, 1679-1684.
177. Hadden, M.K.; Hill, S.A.; Davenport, J.; Matts, R.L.; Blagg, B.S. Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorg. Med. Chem. 2009, 17, 634-640.
178. Zhao, H.; Brandt, G.E.; Galam, L.; Matts, R.L.; Blagg, B.S. Identification and initial SAR of silybin: An Hsp90 inhibitor. Bioorg. Med. Chem. Lett. 2011, 21, 2659-2664.
179. Lim, J.H.; Park, J.W.; Choi, K.S.; Park, Y.B.; Kwon, T.K. Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells. Carcinogenesis 2009, 30, 729-736.
180. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C.J.; McLauchlan, H.; Klevernic, I.; Arthur, J.S.; Alessi, D.R.; Cohen, P. The selectivity of protein kinase inhibitors: A further update. Biochem. J. 2007, 408, 297-315.
181. Prasad, S.; Ravindran, J.; Sung, B.; Pandey, M.K.; Aggarwal, B.B. Garcinol potentiates TRIAL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol. Cancer Ther. 2010, 9, 856-868.
182. Parasramka, M.A.; Gupta, S.V. Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells. Nutr. Cancer 2011, 63, 456-465.
183. Ahmad, A.; Sarkar, S.H.; Aboukameel, A.; Ali, S.; Biersack, B.; Seibt, S.; Li, Y.; Bao, B.; Kong, D.; Banerjee, S.; et al. Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. Carcinogenesis 2012, 33, 2450-2456.
184. Hong, J.; Sang, S.; Park, H.J.; Kwon, S.J.; Suh, N.; Huang, M.T.; Ho, C.T.; Yang, C.S. Modulation of arachidonic acid metabolism and nitric oxide synthesis by garcinol and its derivatives. Carcinogenesis 2006, 27, 278-286.
185. Tanaka, T.; Kohno, H.; Shimada, R.; Kagami, S.; Yamaguchi, F.; Kataoka, S.; Ariga, T.; Murakami, A.; Koshimizu, K.; Ohigashi, H. Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats. Carcinogenesis 2000, 21, 1183-1189.
186. Son, D.J.; Kim, S.Y.; Han, S.S.; Kim, C.W.; Kumar, S.; Park, B.S.; Lee, S.E.; Yun, Y.P.; Jo, H.; Park, Y.H. Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling. Biochem. Biophys. Res. Commun. 2012, 427, 349-354.
187. Golovine, K.V.; Makhov, P.B.; Teper, E.; Kutikov, A.; Canter, D.; Uzzo, R.G.; Kolenko, V.M. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 2013, 73, 23-30.
188. Bezerra, D.P.; Pessoa, C.; de Moraes, M.O.; Saker-Neto, N.; Silveira, E.R.; Costa-Lotufo, L.V. Overview of the therapeutic potential of piplartine (piperlongumine). Eur. J. Pharm. Sci. 2012, 48, 453-463.
189. Uma, S.; Hartson, S.D.; Chen, J.J.; Matts, R.L. Hsp90 is obligatory for the heme-regulated eIF-2alpha kinase to acquire and maintain an activable conformation. J. Biol. Chem. 1997, 272, 11648-11656.
190. Eskew, J.D.; Sadikot, T.; Morales, P.; Duren, A.; Dunwiddie, I.; Swink, M.; Zhang, X.; Hembruff, S.; Donnelly, A.; Rajewski, R.A.; et al. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 2011, 11, 468.
191. Axerio-Cilies, P.; Castaneda, I.P.; Mirza, A.; Reynisson, J. Investigation of the incidence of "Undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds. Eur. J. Med. Chem. 2009, 44, 1128-1134.
192. Benigni, R.; Bossa, C. Mechanisms of chemical carcinogenicity and mutagenicity: A review with implications for predictive toxicology. Chem. Rev. 2011, 111, 2507-2536.
193. Baell, J.B. Observations on screening-based research and some concerning trends in the literature. Future Med. Chem. 2010, 2, 1529-1546.
194. Baell, J.B.; Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 53, 2719-2740.
195. Bauer, R.A.; Wurst, J.M.; Tan, D.S. Expanding the range of 'druggable' targets with natural product-based libraries: An academic perspective. Curr. Opin. Chem. Biol. 2010, 14, 308-314.
196. Ganesan, A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 2008, 12, 306-317.
197. Ross, D. Quinone reductases multitasking in the metabolic world. Drug Metab. Rev. 2004, 36, 639-654.
198. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L.R.; Padera, R.F.; Shapiro, G.I.; Baum, A.; Himmelsbach, F.; et al. BIBW2992, an irreversible EGFR/Her2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27, 4702-4711.
199. Hong, Y.; Yu, B.; Sherman, M.; Yuan, Y.C.; Zhou, D.; Chen, S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol. Endocrinol. 2007, 21, 401-414.
200. Matts, R.L.; Brandt, G.E.; Lu, Y.; Dixit, A.; Mollapour, M.; Wang, S.; Donnelly, A.C.; Neckers, L.; Verkhivker, G.; Blagg, B.S. A systematic protocol for the characterization of Hsp90 modulators. Bioorg. Med. Chem. 2011, 19, 684-692.